AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Why AC Immune Stock Zoomed Almost 15% Higher Today
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune (ACIU) Upgraded to Buy: Here's Why
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
New Strong Sell Stocks for August 6th
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for March 5th
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)
New Strong Buy Stocks for January 31st
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
Alzheimer's vaccine licensing deal boosts AC Immune
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround